CD19.SB9.CAR-EBVST / Tikva Allocell - LARVOL DELTA

Tikva Allocell Selected to Present Preclinical CD19.SB9.CAR-EBVST Data at ACR Convergence 2026 (PRNewswire) - "Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus. Preclinical research evaluating CD19.SB9.CAR-EBVST in systemic lupus erythematosus (SLE) has been accepted for oral presentation at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, taking place November 6–11, 2026, in Orlando, Florida."

Preclinical • Systemic Lupus Erythematosus